On October 10, the EGFR-LYTAC project consortium met in person at the facilities of the Center for Genomic Regulation (CRG), one of the project partners. During the meeting, the participants reviewed the status of each task and defined the next steps to ensure the proper development of the project.
The EGFR-LYTAC project, funded under the PCPP 2023 call, aims to develop a new therapy to combat a specific type of hard-to-treat lung cancer. To achieve this, specific antibodies are used that act as “smart messengers”: they target the EGFR protein, which helps cancer cells grow, and eliminate it from within the cell.
This approach combines two cutting-edge technologies:
- mAbLYTACs, which enable the cell to destroy the target protein.
- ADC, which delivers a toxic drug directly to the tumor cell.
The combination of these strategies could be effective even in cases where other treatments fail, such as tumors resistant due to mutations.
At Leitat, leaders of Task 6, we presented the progress in obtaining antibodies, a key element for the development of this innovative therapeutic strategy.
Project CPP2023-010665 funded by:
